EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass

Antonio Ferreira, Katja A Schönenberger iD, Natascha Potoczna, Andreas Vogt, Philipp A Gerber, Jörg Zehetner, Daniel Giachino, Philipp Nett, Joanna Gawinecka, Luca Cossu iD, Daniel G Fuster, Chiara Dalla Man und 7 weitere

Diabetes Technology & Therapeutics · 2023-07 · 25 (7) · 467-475

DOI: 10.1089/dia.2023.0036 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 28.06.2023. Verfasst von Antonio Ferreira und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerl…. Hauptthemen laut MEDLINE: Gastric Bypass, Hypoglycemia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To investigate the effect of empagliflozin on glucose dynamics in individuals suffering from postbariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass (RYGB).

Methods

Twenty-two adults with PBH after RYGB were randomized to empagliflozin 25 mg or placebo once daily over 20 days in a randomized, double-blind, placebo-controlled, crossover trial. The primary efficacy outcome was the amplitude of plasma glucose excursion (peak to nadir) during a mixed-meal tolerance test (MMTT). Outcomes of the outpatient period were assessed using continuous glucose monitoring (CGM) and an event-tracking app.

Results

The amplitude of glucose excursion during the MMTT was 8.1 ± 2.4 mmol/L with empagliflozin versus 8.1 ± 2.6 mmol/L with placebo (mean ± standard deviation, P = 0.807). CGM-based mean amplitude of glucose excursion during the 20-day period was lower with empagliflozin than placebo (4.8 ± 1.3 vs. 5.2 ± 1.6. P = 0.028). Empagliflozin reduced the time spent with CGM values >10.0 mmol/L (3.8 ± 3.5% vs. 4.7 ± 3.8%, P = 0.009), but not the time spent with CGM values

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastric BypassHypoglycemiaAdultHumansBlood GlucoseBlood Glucose Self-MonitoringCross-Over StudiesGlucoseDouble-Blind MethodBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

Bariatric surgeryGlucose variabilityHypoglycemiaPostprandial glucose metabolismRoux-en-Y gastric bypassSGLT2 inhibition

Substanzen

Blood GlucoseGlucoseempagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
  • Stoffwechselpraxis, Stoffwechselzentrum Hirslanden Clinic St. Anna, Lucerne, Switzerland.
  • Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ) and University of Zurich (UZH), Zurich, Switzerland.
  • Department of Visceral Surgery, Hirslanden Clinic Beau-Site, Bern, Switzerland.

ORCID-Profile: Katja A Schönenberger, Luca Cossu, Lia Bally

Zitieren

APA

Ferreira, A., Schönenberger, K. A., Potoczna, N., Vogt, A., Gerber, P. A., Zehetner, J., Giachino, D., Nett, P., Gawinecka, J., Cossu, L., Fuster, D. G., Dalla Man, C., Facchinetti, A., Melmer, A., Nakas, C. T., Hepprich, M., Donath, M. Y., Herzig, D., & Bally, L. (2023). Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass. Diabetes Technology & Therapeutics, 25(7), 467-475. https://doi.org/10.1089/dia.2023.0036

Vancouver

Ferreira A, Schönenberger KA, Potoczna N, Vogt A, Gerber PA, Zehetner J, et al. Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass. Diabetes Technology & Therapeutics. 2023;25(7):467-475. doi:10.1089/dia.2023.0036

BibTeX
@article{Ferreira2023,
  author = {Ferreira, Antonio and Schönenberger, Katja A and Potoczna, Natascha and Vogt, Andreas and Gerber, Philipp A and Zehetner, Jörg and Giachino, Daniel and Nett, Philipp and Gawinecka, Joanna and Cossu, Luca and Fuster, Daniel G and Dalla Man, Chiara and Facchinetti, Andrea and Melmer, Andreas and Nakas, Christos T and Hepprich, Matthias and Donath, Marc Y and Herzig, David and Bally, Lia},
  title = {Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass},
  journal = {Diabetes Technology & Therapeutics},
  year = {2023},
  volume = {25},
  number = {7},
  pages = {467--475},
  doi = {10.1089/dia.2023.0036}
}
Kostenlos starten →